Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27717809 | 0.98 | CYP19A1 (0.50) | CYP19A1BCHENPC1RAB9AMEN1 | |
| SCHEMBL9530751 | 0.74 | CYP19A1 (0.52) | CYP19A1BCHENPC1RAB9AKMT2A | |
| SCHEMBL28316960 | 0.74 | CYP19A1 (0.52) | CYP19A1BCHENPC1RAB9AMEN1 | |
| SCHEMBL5326554 | 0.74 | CYP19A1 (0.52) | CYP19A1BCHENPC1RAB9AMEN1 | |
| SCHEMBL16754127 | 0.74 | CYP19A1 (0.52) | CYP19A1BCHENPC1RAB9AMEN1 | |
| SCHEMBL2687071 | 0.74 | KMT2A (0.52) | CYP19A1BCHENPC1RAB9AKMT2A | |
| SCHEMBL16090317 | 0.74 | CYP19A1 (0.52) | CYP19A1BCHENPC1RAB9AMEN1 | |
| SCHEMBL27824322 | 0.74 | DAGLA (0.54) | CYP19A1MEN1KMT2ACASP3SENP8 | |
| SCHEMBL1119554 | 0.72 | PTGS2 (0.66) | CYP19A1BCHEPTGS2CA12CA1 | |
| SCHEMBL16206235 | 0.72 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907279-A | Synthesis method of N-oxyphenyltriazole | 金华职业技术学院 | 2022-08-16 | — | — | CN | claimed |
| CN-114317127-A | Fluoride-free cleaning agent, and preparation method and application thereof | 嘉庚创新实验室 | 2022-04-12 | — | — | CN | claimed |
| CN-111871457-A | Catalytic liquid for straw biomass and continuous treatment process | 南京工业大学 | 2020-11-03 | — | — | CN | claimed |
| US-6677483-B2 | DISSOLVING DIETHYLENETRIAMINEPENTAACETIC- BISANHYDRIDE OF FORMULA IN DIMETHYL SULFOXIDE OR IN DIMETHYLFORMAMIDE OR IN A MIXTURE; ADDING SOLUBILIZER, AN AUXILIARY BASE AND A MONOAMINE OR DIAMINE, HEATING | SCHERING AG (DE) | 2004-01-13 | — | — | US | claimed |
| EP-1353897-A1 | METHOD FOR PRODUCING DTPA MONOAMIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-22 | — | — | EP | claimed |
| US-20020155065-A1 | Process for the production of monoamides of DTPA | SCHERING AG (DE) | 2002-10-24 | — | — | US | claimed |
| WO-2002059076-A1 | METHOD FOR PRODUCING DTPA MONOAMIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-08-01 | — | — | WO | claimed |
| CN-114907279-A | Synthesis method of N-oxyphenyltriazole | 金华职业技术学院 | 2022-08-16 | — | — | CN | disclosed |
| CN-114907279-A | Synthesis method of N-oxyphenyltriazole | 金华职业技术学院 | 2022-08-16 | — | — | CN | disclosed |
| CN-114907279-A | Synthesis method of N-oxyphenyltriazole | 金华职业技术学院 | 2022-08-16 | — | — | CN | disclosed |
| CN-111875668-B | Synthetic method of cyclic dipeptide containing glutamine or asparagine | 陕西慧康生物科技有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-109311825-B | 2,4, 6-trisubstituted s-triazine compound and preparation method and application thereof | 南京世其医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109666063-B | Maltose functionalized nano composite material based on ion complementary peptide self-assembly and preparation method and application thereof | 陕西师范大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-1171105-A | Use of dioxomorpholines for combating endoparasites, dioxomorpholines and process for their preparation | BAYER AG (DE) | 1998-01-21 | — | — | CN | disclosed |
| US-5672585-A | HYDROPHOBIC AND CATIONIC AMINO ACID-CONTAINING CYCLIC (POLY)PEPTIDES HAVING HIGH AFFINITY FOR GLYCOPROTEIN IIB/IIIA RECEPTORS TO INHIBIT PLATELET AGGREGATION WITHOUT PROLONGED BLEEDING | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-09-30 | — | — | US | disclosed |
| CN-1125938-A | Bicyclic amide derivatives and their use as muscle relaxants | WELLCOME FOUND (GB) | 1996-07-03 | — | — | CN | disclosed |
| EP-0705274-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1996-04-10 | — | — | EP | disclosed |
| CN-1106811-A | Piperidines and piperazines | MERCK PATENG GES MIT BESCHRAEN (DE) | 1995-08-16 | — | — | CN | disclosed |
| WO-1995000544-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-01-05 | — | — | WO | disclosed |
| EP-0410767-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155065-A1 | Process for the production of monoamides of DTPA | NAAA, PAM, DNPEP | CYP19A1 2094/4885BCHE 292/4885NPC1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.